J2P-MC-LXBD

Developer: Medable Inc.

Category: Health & Fitness

Add App to Comparison

ASO Keyword Dashboard

Tracking 15 keywords for J2P-MC-LXBD in Google Play

Developer: Medable Inc. Category: health_and_fitness

J2P-MC-LXBD tracks 15 keywords (no keywords rank yet; 15 need traction). Key metrics: opportunity 71.8, difficulty 37.5.

Phase 2b study of Diabetic Peripheral Neuropathic Pain

Tracked keywords

0 ranked • 15 not ranking yet

Top 10 coverage

—

Best rank — • Latest leader —

Avg opportunity

71.8

Top keyword: participants

Avg difficulty

37.5

Lower scores indicate easier wins

Opportunity leaders

participants

Opportunity: 74.0 • Difficulty: 36.9 • Rank —

Competitors: 78
60.8
evaluate

Opportunity: 74.0 • Difficulty: 38.4 • Rank —

Competitors: 165
63.1
adult

Opportunity: 74.0 • Difficulty: 40.3 • Rank —

Competitors: 505
60.6
ranging

Opportunity: 74.0 • Difficulty: 40.8 • Rank —

Competitors: 414
61.8
phase

Opportunity: 73.0 • Difficulty: 36.4 • Rank —

Competitors: 157
58.1

Unranked opportunities

participants

Opportunity: 74.0 • Difficulty: 36.9 • Competitors: 78
evaluate

Opportunity: 74.0 • Difficulty: 38.4 • Competitors: 165
adult

Opportunity: 74.0 • Difficulty: 40.3 • Competitors: 505
ranging

Opportunity: 74.0 • Difficulty: 40.8 • Competitors: 414
phase

Opportunity: 73.0 • Difficulty: 36.4 • Competitors: 157

High competition keywords

levels

Total apps: 66,513 • Major competitors: 4,983

Latest rank: — • Difficulty: 52.2
study

Total apps: 53,695 • Major competitors: 1,147

Latest rank: — • Difficulty: 48.0
safety

Total apps: 36,993 • Major competitors: 1,246

Latest rank: — • Difficulty: 53.3
evaluate

Total apps: 9,189 • Major competitors: 165

Latest rank: — • Difficulty: 38.4
ranging

Total apps: 7,564 • Major competitors: 414

Latest rank: — • Difficulty: 40.8

All tracked keywords

Includes opportunity, difficulty, rankings and competitor benchmarks

							Major Competitors
participants	74	100	37	61 6,527 competing apps Median installs: 531 Avg rating: 1.8	—	—	78 major competitor apps
phase	73	100	36	58 4,477 competing apps Median installs: 908 Avg rating: 1.9	—	—	157 major competitor apps
levels	69	100	52	77 66,513 competing apps Median installs: 3,769 Avg rating: 2.2	—	—	4,983 major competitor apps
bid	73	100	35	56 3,129 competing apps Median installs: 1,334 Avg rating: 2.1	—	—	109 major competitor apps
study	70	100	48	75 53,695 competing apps Median installs: 1,121 Avg rating: 1.8	—	—	1,147 major competitor apps
pain	73	100	35	57 3,749 competing apps Median installs: 1,614 Avg rating: 2.0	—	—	105 major competitor apps
evaluate	74	100	38	63 9,189 competing apps Median installs: 1,863 Avg rating: 1.8	—	—	165 major competitor apps
safety	71	100	53	73 36,993 competing apps Median installs: 982 Avg rating: 1.8	—	—	1,246 major competitor apps
adult	74	100	40	61 6,360 competing apps Median installs: 4,556 Avg rating: 2.3	—	—	505 major competitor apps
ranging	74	100	41	62 7,564 competing apps Median installs: 2,399 Avg rating: 2.1	—	—	414 major competitor apps
peripheral	70	100	29	42 434 competing apps Median installs: 2,193 Avg rating: 2.0	—	—	21 major competitor apps
dose	73	100	38	57 3,879 competing apps Median installs: 1,248 Avg rating: 2.0	—	—	144 major competitor apps
diabetic	69	100	26	41 368 competing apps Median installs: 1,439 Avg rating: 2.0	—	—	9 major competitor apps
efficacy	70	100	26	42 443 competing apps Median installs: 192 Avg rating: 1.6	—	—	5 major competitor apps
administered	70	100	27	45 647 competing apps Median installs: 1,302 Avg rating: 2.0	—	—	7 major competitor apps

App Description

Phase 2b study of Diabetic Peripheral Neuropathic Pain

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to evaluate the efficacy and safety of 3 dose levels of BID administered LY3556050 in Adult Participants with Diabetic Peripheral Neuropathic Pain.